Notice of Results and Investor Presentation

Summary by AI ^BETAClose X

Vulcan Two Group plc will release its Full Year Results on Thursday, May 21, 2026, and will host a live investor presentation at 12:30pm BST via the Investor Meet Company platform. The management team will discuss the company's vision, buy-and-build strategy, and the growth opportunities in the UK ePharmacy market. The company is focused on becoming the UK's leading regulated ePharmacy platform, having recently acquired CloudRx, Webmed, and Hyperdrug, establishing a diversified and profitable business with recurring revenues and strong cash generation.

Disclaimer*

Vulcan Two Group PLC

18 May 2026

Vulcan Two Group plc

(the "Company", "Group" or "Vulcan Two")

Notice of Results and Investor Presentation

Following the release of the Company's Full Year Results on Thursday 21 May 2026, the management team of Vulcan Two Group plc, the company aiming to create the UK's leading regulated ePharmacy through buy-and-build, will be hosting a live presentation at 12:30pm (BST) via the Investor Meet Company platform.

Michael Kraftman (CEO), Keith Butcher (CFO) and Brendan O'Brien (COO) will present an overview of the Company's vision, its proven buy-and-build strategy, and the significant growth opportunity within the UK ePharmacy market.

The presentation is open to all existing and potential shareholders and registration can be completed via the following link: www.investormeetcompany.com/vulcan-two-group-plc/register-investor

Questions can be submitted pre-event via your Investor Meet Company dashboard up until 9:00am the day before the meeting or at any time during the live presentation.

For further information please contact:

Vulcan Two Group plc

Michael Kraftman, Chief Executive Officer

Keith Butcher, Chief Finance Officer

Brendan O'Brien, Chief Operating Officer

www.vulcantwo.com

Email: info@vulcantwo.com

Canaccord Genuity Limited
(Nominated Adviser and Sole Broker)

Simon Bridges / Harry Pardoe / Elizabeth Halley-Stott

Tel: +44 (0) 20 7523 8000

Alma Strategic Communications
(Financial PR)

Justine James / Sam Modlin / Will Merison

Email: vulcantwo@almastrategic.com

Tel: +44 (0) 20 3405 0205

Notes to Editors

Vulcan Two Group plc (AIM:VUL) is creating the UK's leading regulated ePharmacy platform, through its disciplined buy-and-build strategy. Following the acquisitions of CloudRx, Webmed and Hyperdrug in March 2026, the Group has established a diversified, profitable platform spanning B2B prescription fulfilment and B2C digital pharmacy services, with a high proportion of recurring revenues and strong cash generation. Future growth is expected to be supported through the acquisition of complementary businesses, expansion into new sectors or markets, and investment in long-term assets.

The Group is led by an experienced management team with deep healthcare, eCommerce and buy-and-build expertise.

For more information, visit www.vulcantwo.com

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.

END